Results
|
1.
|
|
|
2.
|
|
|
3.
|
|
|
4.
|
|
|
5.
|
Exploring residual risk for diabetes and microvascular disease in the Diabetes Prevention Program Outcomes Study (DPPOS). MedStar authors:
Year: 2017
Citation: - Diabetic Medicine. 34(12):1747-1755, 2017 Dec.
Institution: - MedStar Health Research Institute
Medline publication type:
All authors: - Aroda VR, Barrett-Connor E, Dabelea D, Dagogo-Jack S, Hamman RF, Kahn SE, Knowler WC, Mather KJ, Pan Q, Perreault L, The Diabetes Prevention Program Research Group
|
|
6.
|
Target organ damage and incident type 2 diabetes mellitus: the Strong Heart Study. MedStar authors:
Year: 2017
Citation: - Cardiovascular Diabetology. 16(1):64, 2017 05 12
Institution: - MedStar Health Research Institute
Medline publication type:
All authors: - Best LG, de Simone G, Devereux RB, Howard BV, Izzo R, Lee ET, Mancusi C, Roman MJ, Wang W, Yeh F
|
|
7.
|
Neuropsychiatric safety with liraglutide 3.0mg for weight management: results from randomized controlled phase 2 and 3a trials. MedStar authors:
Year: 2017
Citation: - Diabetes, Obesity & Metabolism. 19(11):1529-1536, 2017 Nov.
Institution: - MedStar Health Research Institute
Medline publication type:
All authors: - Aroda VR, Astrup A, Brett J, Cancino A, Kushner R, Lau DC, O'Neil PM, Satiety and Clinical Adiposity - Liraglutide Evidence in individuals with and without diabetes (SCALE) study groups, Wadden TA, Wilding JP
|